A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg twice daily, 500mcg twice daily, and placebo twice daily via the DISKUSĀ® inhaler in subjects with chronic obstructive pulmonary disease (COPD).
fluticasone propionate
Pulmonary Disease, Chronic Obstructive
Phase 3
An analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013